Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting

•Patients with atrial fibrillation (AF) are at high risk of costly post-percutaneous coronary intervention (PCI) complications.•Recent trials have explored antithrombotic options after PCI in patients with AF.•Non-vitamin K antagonist oral anticoagulant-based regimens were associated with lower bleeding risk than vitamin K antagonist-based options.•This benefit may lead to lower costs overall in addition to better overall outcomes.